REVB — Revelation Biosciences Share News
0.000.00%
Last trade - 00:00Brief: Revelation Biosciences Announces Phase 1 Clinical Study Of Gemini Met The Primary Safety Endpoint And Showed Statistically Significant Biomarker Activity
Brief: Revelation Biosciences Inc. Q1 EPS USD -2.46
Brief: Revelation BiosciencesAnnounces Financial Results
Brief: Revelation Biosciences Commences First In Human Phase 1 Clinical Study Of Gemini
Brief: Revelation Biosciences Announces Pricing of $6.2 Mln Public Offering
Brief: Revelation Biosciences Inc. Announces 1-For-30 Reverse Stock Split Effective January 25, 2024
Brief: Gemini Induces Pharmacologic Activity And Related Physiologic Changes In Multiple Preclinical Studies
Brief: Revelation Biosciences Inc Announces Appointment Of Lakhmir Chawla, M.D. To Board Of Directors
Revelation Biosciences Inc reports results for the quarter ended in June - Earnings Summary
Revelation Biosciences Inc expected to post a loss of 33 cents a share - Earnings Preview
Brief: Revelation Biosciences Inc. Q2 EPS USD -0.25
Brief: Revelation Biosciences Inc Reports Notice Of Delisting From Nasdaq On Aug 8
Brief: Revelation Biosciences Adjourns 2023 Annual Meeting Of Stockholders To July 7
Brief: Revelation Biosciences Inc. Announces Financial Results For The Three Months Ended March 31
Brief: Revelation Biosciences Inc Reports Quarterly Loss Per Share Of $1.77
Brief: Revelation Biosciences Received Nasdaq Notice Stating Co's Common Stock Will Continue To Be Listed, Traded On Nasdaq
Brief: Revelation Bio Announces Preclinical Biomarker Data Supporting Activity Of REVTx-300
Brief: Revelation Biosciences Inc. Announces 1-For-35 Reverse Stock Split Effective February 1, 2023 And Results Of Special Meeting Of Stockholders
Brief: Revelation Biosciences Will Be Mandatorily Separated & Units To No Longer Trade On Nasdaq